Long term results of a prospective dose escalation phase-II trial: Interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer

Radiotherapy and Oncology

Volumn 104, Issue 2, 2012, Pages 181-186

  Lettmaier, Sebastian ^a   Lotter, Michael ^a   Kreppner, Stephan ^a   Strnad, Annedore ^a   Fietkau, Rainer ^a   Strnad, Vratislav ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Boost; Brachytherapy; Dose escalation; Prostate cancer

Indexed keywords

AGED; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER GROWTH; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTROLLED STUDY; CYSTITIS; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; PROSTATE CANCER; PULSED DOSE RATE BRACHYTHERAPY; RADIATION INJURY; RECURRENCE FREE SURVIVAL; URINARY FREQUENCY; URINARY URGENCY;

AGED; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME; TREATMENT OUTCOME;

EID: 84865720928     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.07.003     Document Type: Article

References (41)

1. A.V. D'Amico, A. Desjardin, and A. Chung Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy Cancer 82 1998 1887 1896
2. E.P. Armour, J.R. White, and A. Armin Pulsed low dose rate brachytherapy in a rat model: dependence of late rectal injury on radiation pulse size Int J Radiat Oncol Biol Phys 38 1997 825 834
3. D.J. Brenner, P.B. Schiff, Y. Huang, and E.J. Hall Pulsed-dose-rate brachytherapy: design of convenient (daytime-only) schedules Int J Radiat Oncol Biol Phys 39 1997 809 815
4. J.F. Fowler, and E.F. Van Limbergen Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues Int J Radiat Oncol Biol Phys 37 1997 877 883
5. P. Fritz, C. Frank, and K.J. Weber In vitro studies of PDR brachytherapy Strahlenther Onkol 174 1998 365 374
6. E.J. Hall, and D.J. Brenner Pulsed dose-rate brachytherapy Radiother Oncol 45 1997 1 2
7. E. Lartigau Is "pulse dose rate" curietherapy comparable to low dose rate brachytherapy? Bull Cancer Radiother 82 1995 336 339
8. K.A. Mason, H.D. Thames, T.G. Ochran, A.C. Ruifrok, and N. Janjan Comparison of continuous and pulsed low dose rate brachytherapy: biological equivalence in vivo Int J Radiat Oncol Biol Phys 28 1994 667 671
9. L.A. Pop, J.F. van den Broek, A.G. van der Visser, and A.J. Kogel Constraints in the use of repair half times and mathematical modelling for the clinical application of HDR and PDR treatment schedules as an alternative for LDR brachytherapy Radiother Oncol 38 1996 153 162
10. P.S. Swift, P. Purser, L.W. Roberts, B. Pickett, C.B. Powell, and T.L. Phillips Pulsed low dose rate brachytherapy for pelvic malignancies Int J Radiat Oncol Biol Phys 37 1997 811 817
11. C.L. Rogers, J.H. Freel, and B.L. Speiser Pulsed low dose rate brachytherapy for uterine cervix carcinoma Int J Radiat Oncol Biol Phys 43 1999 95 100
12. P.C. Levendag, P.I. Schmitz, and P.P. Jansen Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate Int J Radiat Oncol Biol Phys 38 1997 497 506
13. O.J. Ott, M. Lotter, R. Fietkau, and V. Strnad Accelerated partial-breast irradiation with interstitial implants. Analysis of factors affecting cosmetic outcome Strahlenther Onkol 185 2009 170 176
14. V. Strnad, W. Melzner, and M. Geiger Role of interstitial PDR brachytherapy in the treatment of oral and oropharyngeal cancer. A single-institute experience of 236 patients Strahlenther Onkol 181 2005 762 767
15. V. Strnad, M. Geiger, M. Lotter, and R. Sauer The role of pulsed-dose-rate brachytherapy in previously irradiated head-and-neck cancer Brachytherapy 2 2003 158 163
16. A.G. Visser, G.J. van den Aardweg, and P.C. Levendag Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments Int J Radiat Oncol Biol Phys 34 1996 497 505
17. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
18. C.A. Lawton, K. Winter, and K. Murray Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
19. E.M. Horwitz, K. Winter, G.E. Hanks, C.A. Lawton, A.H. Russell, and M. Machtay Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy Int J Radiat Oncol Biol Phys 49 2001 947 956
20. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
21. J. Laverdiere, J.L. Gomez, and L. Cusan Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer Int J Radiat Oncol Biol Phys 37 1997 247 252
22. C.J. Tyrrell, H. Payne, and W.A. See Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme Radiother Oncol 76 2005 4 10
23. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
24. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
25. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
26. J.S. Stromberg, A.A. Martinez, and E.M. Horwitz Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer J Sci Am 3 1997 346 352
27. M.C. Joiner, and S.M. Bentzen Time-dose relationship: the linear quadratic approach 2002 Arnold London
28. J. Fowler, R. Chappell, and M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
29. S.M. Bentzen, and M.A. Ritter The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol 76 2005 1 3
30. R. Cheung, S.L. Tucker, and A.K. Lee Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy Int J Radiat Oncol Biol Phys 61 2005 993 1002
31. R. Valdagni, C. Italia, and P. Montanaro Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy Radiother Oncol 75 2005 74 82
32. J.C. Blasko, T. Mate, J.E. Sylvester, P.D. Grimm, and W. Cavanagh Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes Semin Radiat Oncol 12 2002 81 94
33. M.H. Seegenschmiedt Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives Strahlenther Onkol 174 1998 25 29
34. M.A. Izard, R.L. Haddad, G.B. Fogarty, A. Rinks, T. Dobbins, and P. Katelaris Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer Int J Radiat Oncol Biol Phys 66 2006 38 47
35. B.R. Pieters, E.D. Geijsen, and K. Koedooder Treatment results of PDR brachytherapy combined with external beam radiotherapy in 106 patients with intermediate- to high-risk prostate cancer Int J Radiat Oncol Biol Phys 79 2011 1037 1042
36. J.E. Sylvester, P.D. Grimm, and J.C. Blasko 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience Int J Radiat Oncol Biol Phys 67 2007 57 64
37. I. Klapan, F. Culo, and J. Culig Arachidonic acid metabolites and sinonasal polyposis. I. Possible prognostic value Am J Otolaryngol 16 1995 396 402
38. D.J. Demanes, R.R. Rodriguez, L. Schour, D. Brandt, and G. Altieri High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results Int J Radiat Oncol Biol Phys 61 2005 1306 1316
39. C.E. Vargas, A.A. Martinez, and T.P. Boike High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study Int J Radiat Oncol Biol Phys 66 2006 416 423
40. B.R. Pieters, J.B. van de Kamer, and Y.R. van Herten Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy Radiother Oncol 88 2008 46 52
41. P.J. Hoskin, A.M. Rojas, P.J. Bownes, G.J. Lowe, P.J. Ostler, and L. Bryant Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer Radiother Oncol 103 2012 217 222